Journal: Molecular Medicine Reports

Article Title: A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

doi: 10.3892/mmr.2022.12722

Figure Lengend Snippet: BM-MSCs characterization. (A) BM-MSCs were adherent to the culture flask and presented elongated morphology (scale bar, 100 µm). They also expressed high mesenchymal markers, such as (B) CD90 and (C) CD105 (scale bar, 100 µm). In addition, they could differentiate to chondrogenic by (D) Alcian blue staining and calcified areas generated by osteogenic cells with (E) Von Kossa stain. BM-MSCs, bone marrow mesenchymal stem cells.

Article Snippet: MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions.

Techniques: Staining, Generated

Journal: Molecular Medicine Reports

Article Title: A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

doi: 10.3892/mmr.2022.12722

Figure Lengend Snippet: Lentiviral transduction of BM-MSC. (A-C) Lentiviral vectors were designed to contain (A) sTRAIL, (B) flTRAIL and (C) IFNβ. (D) Representative fluorescent images of BM-MSCs transduced with lentiviral vectors; nucleus stained with DAPI (blue) and transduced BM-MSCs expressing GFP protein (green signal). (E and F) Western blot analysis confirming protein expression of (E) flTRAIL and sTRAIL (F) and IFNβ in untransfected MSCs and MSCs transduced with a lentivirus that does not contain any of the genes of interest (empty lentiviral vector pLV[Exp]-EGFP:T2A:Puro-EF1A> mCherry, Vector Builder). MSCs express each of the genes flTRAIL, sTRAIL and IFN and as positive control the recombinant protein. Actin was used as a loading control. BM-MSCs, bone marrow mesenchymal stem cells; sTRAIL, TRAIL soluble; flTRAIL, TRAIL full length; IFNβ, interferon β.

Article Snippet: MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions.

Techniques: Transduction, Staining, Expressing, Western Blot, Plasmid Preparation, Positive Control, Recombinant, Control

Journal: Molecular Medicine Reports

Article Title: A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

doi: 10.3892/mmr.2022.12722

Figure Lengend Snippet: Kaplan-Meier curves. (A) First model with all treatments. (B) Second model with sTRAIL and IFNβ treatment and MSC naïve. *P<0.05 and **P<0.001 compared with the untreated group. sTRAIL, TRAIL soluble; IFNβ, interferon β; MSC, mesenchymal stem cell.

Article Snippet: MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions.

Techniques:

Journal: Cell Death & Disease

Article Title: Zebularine regulates early stages of mESC differentiation: effect on cardiac commitment

doi: 10.1038/cddis.2013.88

Figure Lengend Snippet: Characterization of HS-181 cell line after treatment with zebularine. ( a ) RT-PCR of cardiac markers after treatment with zebularine. Myh7, Myh6, Actc, cTnI and Serca2 present more expression after treatment. ( b ) Immunostaining of treated cells to detect cardiac-specific proteins. Scale bars; 50 μ m. ( c ) Blots of Proteome Profiler Array and the resulting quantification histograms demonstrating inhibition of pluripotency marker expression and ( d ) increased levels of mesodermic proteins after zebularine treatment (black arrows)

Article Snippet: Protein expression profiles were assayed using the specific human pluripotent Stem Cell array kit ‘Proteome Profiler Array' (R&D Systems Europe, Abingdon, UK; ARY010) following the manufacturer's instructions.

Techniques: Reverse Transcription Polymerase Chain Reaction, Expressing, Immunostaining, Inhibition, Marker

Journal: Oncology reports

Article Title: Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells.

doi: 10.3892/or.2018.6714

Figure Lengend Snippet: Figure 2. RT‑R‑MDA‑MB‑231 cells demonstrate higher levels of CSCs marker CD44, but lower levels of CD24 compared with MDA‑MB‑231 cells. Classical CSCs markers CD44 and CD24 were detected in the low metastatic breast cancer cells MCF‑7 and RT‑R‑MCF‑7 (A) and highly metastatic breast cancer cells MDA‑MB‑231 and RT‑R‑MDA‑MB‑231 (B) using the specific antibodies by western blotting. Data represent mean values ± standard error of the mean of three independent experiments in triplicate. **P<0.01 compared with control. CD, cluster of differentiation; CSCs, cancer stem cells; RT‑R, radioresistant.

Article Snippet: Isolation of CD24low/CD44high breast cancer stem cells was performed using a MagCollect CD24- CD44+ Breast Cancer Stem Cell Isolation kit (R&D Systems, Inc., Minneapolis, MN, USA) following the manufacturer's protocol.

Techniques: Marker, Western Blot, Control

Journal: Oncology reports

Article Title: Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells.

doi: 10.3892/or.2018.6714

Figure Lengend Snippet: Figure 3. RT‑R‑MDA‑MB‑231 cells increase the populations of CD24low/CD44high cells, and expression levels of other CSCs markers Notch‑4, Oct‑3/4 and ALDH1. (A) CD24low/CD44high cells were isolated from MDA‑MB‑231 and RT‑R‑MDA‑MB cells, and then the number of CD24low/CD44high breast cancer stem cells was quantified by flow cytometry. (B) MDA‑MB‑231 and RT‑R‑MDA‑MB‑231 were labeled with anti‑CD24 and anti‑CD44 antibodies, and the percentages of CD24 or CD44‑expressed subpopulation in cells were determined by flow cytometry. (C) Other cancer stem cell markers, including Notch‑4, Oct3/4 and ALDH1 were detected in the MDA‑MB‑231 and RT‑R‑MDA‑MB‑231 cells using the specific antibodies by western blotting. Data represent mean values ± standard error of the mean of three independent experiments in triplicate. *P<0.05 and **P<0.01 compared with MDA‑MB‑231 cells. ALDH1, aldehyde dehydrogenase 1; CD, cluster of differentiation; CSCs, cancer stem cells; Oct, octamer‑binding transcription factor; RT‑R, radioresistant.

Article Snippet: Isolation of CD24low/CD44high breast cancer stem cells was performed using a MagCollect CD24- CD44+ Breast Cancer Stem Cell Isolation kit (R&D Systems, Inc., Minneapolis, MN, USA) following the manufacturer's protocol.

Techniques: Expressing, Isolation, Flow Cytometry, Labeling, Western Blot